Avidity Biosciences is a privately held biotech company pioneering a new class of precision medicines – Antibody-siRNA Conjugates (ASC) – which combine the strengths of monoclonal antibodies and siRNA-based therapeutics to overcome barriers to the delivery of siRNA and target genetic drivers of disease.

Using our ASC platform, we have generated in vitro and in vivo data that demonstrate knockdown of messenger RNA in multiple important cell types and tissues, including tumor, muscle, heart, lung, liver and B cells. ASCs have drug-like properties comparable to antibodies and antibody-drug conjugates.

Our leadership includes entrepreneurs and scientists with deep expertise in the fields of antibody conjugation, chemistry, formulations, oligonucleotide therapeutics, drug delivery and cancer biology.  Our employees are high energy, creative people who are passionate about solving hard problems and bringing new drugs to patients.

We strive to work with partners to discover best-in-class molecules with the goal of long-term, joint value creation. We have entered research collaborations with leading biopharma companies and are actively seeking additional partnerships. We have raised $25 million in venture financing from a top-tier group of investors, including Takeda Ventures, Alethea Capital, Alexandria Real Estate Equities, Brace Pharma, EcoR1 Capital, F-Prime Capital, Moore Venture Partners, and Tavistock Life Sciences.